"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2021/0381526 A1,169-517-366-514-817,2021-12-09,2021,US 202117445841 A,2021-08-25,US 202117445841 A;;US 201916728678 A;;US 201962842107 P;;US 201862785384 P,2018-12-27,PORTABLE FAN,"The present invention is directed to a portable fan for the use in firefighting and other ventilation use-cases. The portable fan provides firefighters the ability to provide positive pressure ventilation in use for fighting fires which does not require power cables or combustible fuel powered motors, and provides increased portability, reduced risk, and reduced deployment time associated with managing and fighting a fire.",SUPER VACUUM MFG COMPANY INC,WEINMEISTER ROGER;;FALLOON THOMAS,,https://lens.org/169-517-366-514-817,Patent Application,yes,6,0,9,9,0,F04D19/002;;F04D29/601;;F04D25/0673;;F04D29/522;;F04D25/084;;A62C3/0207;;F04D29/522;;F04D25/0673;;F04D29/002;;A62C3/0207;;F04D25/08,F04D29/52;;F04D25/06;;F04D29/00,,0,0,,,,ACTIVE
2,US,A1,US 2020/0208654 A1,003-353-605-977-512,2020-07-02,2020,US 201916728678 A,2019-12-27,US 201916728678 A;;US 201962842107 P;;US 201862785384 P,2018-12-27,PORTABLE FAN,"The present invention is directed to a portable fan for the use in firefighting and other ventilation use-cases. The portable fan provides firefighters the ability to provide positive pressure ventilation in use for fighting fires which does not require power cables or combustible fuel powered motors, and provides increased portability, reduced risk, and reduced deployment time associated with managing and fighting a fire.",SUPER VACUUM MFG COMPANY INC,WEINMEISTER ROGER;;FALLOON THOMAS,SUPER VACUUM MANUFACTURING COMPANY INC (2019-12-26),https://lens.org/003-353-605-977-512,Patent Application,yes,0,10,9,9,0,F04D19/002;;F04D29/601;;F04D25/0673;;F04D29/522;;F04D25/084;;A62C3/0207;;F04D29/522;;F04D25/0673;;F04D29/002;;A62C3/0207;;F04D25/08,F04D29/52;;F04D25/06;;F04D29/00,,0,0,,,,ACTIVE
3,WO,A1,WO 2020/140033 A1,138-404-816-362-369,2020-07-02,2020,US 2019/0068740 W,2019-12-27,US 201916728678 A;;US 201862785384 P;;US 201962842107 P,2018-12-27,PORTABLE FAN,"The present invention is directed to a portable fan for the use in firefighting and other ventilation use-cases. The portable fan provides firefighters the ability to provide positive pressure ventilation in use for fighting fires which does not require power cables or combustible fuel powered motors, and provides increased portability, reduced risk, and reduced deployment time associated with managing and fighting a fire.",SUPER VACUUM MFG COMPANY INC,WEINMEISTER ROGER;;FALLOON THOMAS,,https://lens.org/138-404-816-362-369,Patent Application,yes,11,0,9,9,0,F04D19/002;;F04D29/601;;F04D25/0673;;F04D29/522;;F04D25/084;;A62C3/0207;;F04D29/522;;F04D25/0673;;F04D29/002;;A62C3/0207;;F04D25/08,A62C8/00;;A62C3/02;;A62C31/28;;B62B1/00;;F04D25/08,,1,0,,,"KERBER, STEPHEN ET AL.: ""Go With the Flow: NIST Study Proves PPV Can Save Lives & Improve Safety. Tech Focus"", FIRERESCUE MAGAZINE, 11 December 2019 (2019-12-11)",PENDING
4,AU,A1,AU 2019/414946 A1,175-927-150-728-663,2021-06-24,2021,AU 2019/414946 A,2019-12-27,US 201916728678 A;;US 201862785384 P;;US 201962842107 P;;US 2019/0068740 W,2018-12-27,Portable fan,"The present invention is directed to a portable fan for the use in firefighting and other ventilation use-cases. The portable fan provides firefighters the ability to provide positive pressure ventilation in use for fighting fires which does not require power cables or combustible fuel powered motors, and provides increased portability, reduced risk, and reduced deployment time associated with managing and fighting a fire.",SUPER VACUUM MANUFACTURING COMPANY INC,WEINMEISTER ROGER;;FALLOON THOMAS,,https://lens.org/175-927-150-728-663,Patent Application,no,0,0,9,9,0,F04D19/002;;F04D29/601;;F04D25/0673;;F04D29/522;;F04D25/084;;A62C3/0207;;F04D29/522;;F04D25/0673;;F04D29/002;;A62C3/0207;;F04D25/08,A62C8/00;;A62C3/02;;A62C31/28;;B62B1/00;;F04D25/08,,0,0,,,,ACTIVE
5,US,B2,US 11795970 B2,015-715-549-621-626,2023-10-24,2023,US 202117445841 A,2021-08-25,US 202117445841 A;;US 201916728678 A;;US 201962842107 P;;US 201862785384 P,2018-12-27,Portable fan,"The present invention is directed to a portable fan for the use in firefighting and other ventilation use-cases. The portable fan provides firefighters the ability to provide positive pressure ventilation in use for fighting fires which does not require power cables or combustible fuel powered motors, and provides increased portability, reduced risk, and reduced deployment time associated with managing and fighting a fire.",SUPER VACUUM MFG COMPANY INC,WEINMEISTER ROGER;;FALLOON THOMAS,,https://lens.org/015-715-549-621-626,Granted Patent,yes,10,0,9,9,0,F04D19/002;;F04D29/601;;F04D25/0673;;F04D29/522;;F04D25/084;;A62C3/0207;;F04D29/522;;F04D25/0673;;F04D29/002;;A62C3/0207;;F04D25/08,F04D29/52;;A62C3/02;;F04D25/06;;F04D25/08;;F04D29/00,,3,0,,,"Machine translation of CN-204312958U—Generated Jan. 14, 2022.;;Machine translation of WO-2014/119181A1—Generated Jan. 14, 2022.;;Extended search report for EU Patent App. No. 19902736.8—dated Jan. 20, 2022.",ACTIVE
6,AU,B2,AU 2019/414946 B2,079-942-895-876-287,2021-08-19,2021,AU 2019/414946 A,2019-12-27,US 201916728678 A;;US 201862785384 P;;US 201962842107 P;;US 2019/0068740 W,2018-12-27,Portable fan,"The present invention is directed to a portable fan for the use in firefighting and other ventilation use-cases. The portable fan provides firefighters the ability to provide positive pressure ventilation in use for fighting fires which does not require power cables or combustible fuel powered motors, and provides increased portability, reduced risk, and reduced deployment time associated with managing and fighting a fire.",SUPER VACUUM MANUFACTURING COMPANY INC,WEINMEISTER ROGER;;FALLOON THOMAS,,https://lens.org/079-942-895-876-287,Granted Patent,no,2,0,9,9,0,F04D19/002;;F04D29/601;;F04D25/0673;;F04D29/522;;F04D25/084;;A62C3/0207;;F04D29/522;;F04D25/0673;;F04D29/002;;A62C3/0207;;F04D25/08,A62C8/00;;A62C3/02;;A62C31/28;;B62B1/00;;F04D25/08,,0,0,,,,ACTIVE
7,EP,A1,EP 3902610 A1,042-629-667-323-417,2021-11-03,2021,EP 19902736 A,2019-12-27,US 201862785384 P;;US 201962842107 P;;US 2019/0068740 W,2018-12-27,PORTABLE FAN,,SUPER VACUUM MFG COMPANY INC,WEINMEISTER ROGER;;FALLOON THOMAS,,https://lens.org/042-629-667-323-417,Patent Application,yes,0,0,9,9,0,F04D19/002;;F04D29/601;;F04D25/0673;;F04D29/522;;F04D25/084;;A62C3/0207;;F04D29/522;;F04D25/0673;;F04D29/002;;A62C3/0207;;F04D25/08,A62C8/00;;A62C3/02;;A62C31/28;;B62B1/00;;F04D25/08,,0,0,,,,PENDING
8,EP,A4,EP 3902610 A4,192-625-847-897-777,2022-02-23,2022,EP 19902736 A,2019-12-27,US 201862785384 P;;US 201962842107 P;;US 2019/0068740 W,2018-12-27,PORTABLE FAN,,SUPER VACUUM MFG COMPANY INC,WEINMEISTER ROGER;;FALLOON THOMAS,,https://lens.org/192-625-847-897-777,Search Report,no,4,0,9,9,0,F04D19/002;;F04D29/601;;F04D25/0673;;F04D29/522;;F04D25/084;;A62C3/0207;;F04D29/522;;F04D25/0673;;F04D29/002;;A62C3/0207;;F04D25/08,A62C3/02;;F04D19/00;;F04D25/06;;F04D25/08;;F04D29/52;;F04D29/60;;F16M3/00,,0,0,,,,PENDING
9,US,B2,US 11131321 B2,027-696-042-189-963,2021-09-28,2021,US 201916728678 A,2019-12-27,US 201916728678 A;;US 201962842107 P;;US 201862785384 P,2018-12-27,Portable fan,"The present invention is directed to a portable fan for the use in firefighting and other ventilation use-cases. The portable fan provides firefighters the ability to provide positive pressure ventilation in use for fighting fires which does not require power cables or combustible fuel powered motors, and provides increased portability, reduced risk, and reduced deployment time associated with managing and fighting a fire.",SUPER VACUUM MFG COMPANY INC,WEINMEISTER ROGER;;FALLOON THOMAS,SUPER VACUUM MANUFACTURING COMPANY INC (2019-12-26),https://lens.org/027-696-042-189-963,Granted Patent,yes,4,2,9,9,0,F04D19/002;;F04D29/601;;F04D25/0673;;F04D29/522;;F04D25/084;;A62C3/0207;;F04D29/522;;F04D25/0673;;F04D29/002;;A62C3/0207;;F04D25/08,F04D29/52;;A62C3/02;;F04D25/06;;F04D25/08;;F04D29/00,,2,0,,,"Kerber et al., “Go with the Flow”, Fire Rescue Magazine, Nov. 2009, pp. 36-38.;;International Search Report and Written Opinion in PCT/US19/68740.",ACTIVE
10,US,A,US 5350046 A,032-656-683-655-199,1994-09-27,1994,US 97914992 A,1992-11-23,US 97914992 A;;US 81272491 A,1991-12-23,Luggage case with pull handle,A suitcase having a pull handle. The pull handle is rotatably affixed to the suitcase with a bracket means to assist the user of the suitcase in pulling same across a flat surface in upright position.,AIRWAY IND INC,FALLOON THOMAS;;KIM HYUN S,AIRWAY INDUSTRIES (1993-03-29),https://lens.org/032-656-683-655-199,Granted Patent,yes,22,11,3,3,0,A45C13/262;;A45C13/262,A45C13/26,190/115;;190/127,0,0,,,,EXPIRED
11,CA,A1,CA 2086036 A1,177-572-890-071-129,1993-06-24,1993,CA 2086036 A,1992-12-22,US 81272491 A,1991-12-23,LUGGAGE CASE WITH PULL HANDLE,A suitcase having a pull handle. The pull handle is rotatably affixed to the suitcase with a bracket means to assist the user of the suitcase in pulling same across a flat surface in upright position.,AIRWAY IND INC,FALLOON THOMAS;;KIM HYUN S,,https://lens.org/177-572-890-071-129,Patent Application,no,0,0,3,3,0,A45C13/262;;A45C13/262,A45C13/26,,0,0,,,,DISCONTINUED
12,WO,A1,WO 2016/144675 A1,156-539-437-264-620,2016-09-15,2016,US 2016/0020597 W,2016-03-03,US 201562129268 P;;US 201562244481 P,2015-03-06,VACCINE DOSE AND USE THEREOF,"Disclosed are methods of enhancing respiratory syncytial virus (RSV) immunity in a human subject. The methods encompass administering to a subject a single intramuscular dose of a composition comprising about 20 μg, about 50 μg, 80 μg or about 120 μg RSV soluble F protein. The composition further contains an adjuvant of glucopyranosyl lipid A (GLA) in a squalene-based stable emulsion. The RSV soluble F (sF) protein is amino acids 1-524 of RSV soluble F protein from human strain A2 lacking a transmembrane domain (SEQ ID NO: 1). In some embodiments the subject is human and is at least about 60 years old, or between at least about 60 years old and about 87 years old. In additional embodiments, the method of enhancing RSV immunity in the subject results in enhancing a Th1 biased cellular immune response in the subject, inducing neutralizing antibodies against RSV in the subject, reducing RSV viral titers in the subject, inducing an immune response to RSV in the subject, and/or preventing RSV infection in the subject.",MEDIMMUNE LLC,ESSER MARK THOMAS;;VILLAFANA TONYA LUANA;;FALLOON JUDITH;;DUBOVSKY FILIP,,https://lens.org/156-539-437-264-620,Patent Application,yes,4,5,1,1,13,A61K39/12;;A61K2039/55566;;A61K2039/55572;;A61P31/14;;A61P37/04;;C12N2760/18534,A61K39/00;;A61K39/12;;A61K39/155;;A61K39/39;;A61P31/14;;A61P37/04,,2,2,119-700-489-324-716;;109-170-638-137-247,25793508;;10.1371/journal.pone.0119509;;pmc4368639;;10.1016/j.vaccine.2015.07.025;;26206269,"LAMBERT ET AL.: ""A Novel Respiratory Syncytial Virus (RSV) F Subunit Vaccine Adjuvanted with GLA- SE Elicits Robust Protective TH 1-Type Humoral and Cellular Immunity In Rodent Models"", PLOS ONE, vol. 10, no. 3, 20 March 2015 (2015-03-20), pages 1 - 24, XP055273191;;PATTON ET AL.: ""Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA- SE in cynomolgus macaques"", VACCINE, vol. 33, no. 36, 20 July 2015 (2015-07-20), pages 4472 - 4478, XP055309923",PENDING
13,WO,A1,WO 2014/063168 A1,009-156-000-854-443,2014-04-24,2014,US 2013/0065991 W,2013-10-21,US 201261716118 P,2012-10-19,HETEROCYCLE-BISAMIDE INHIBITORS OF SCAVENGER RECEPTOR BL,"This appl ication describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, wh ich compounds and methods can be used, for example, to med iate h igh-density l ipoprotein (H DL) l ipid uptake and treat hepatitis C vira l infections. The compounds have the formu la : wherein R 1 and R 2 are independently H, halogen, cyano, haloalkyl, ha loa lkyloxy or OMe; or R 1 and R 2 together are -O-CH 2 -O- or -0- CF 2 -O-; R 3 is H, ha logen, cyano, ha loalkyl or ha loa lkyloxy; R 4 is C 1-6 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkylmethyl or C 3-6 cycloheteroalkyl, wherein the heteroatom is N or 0; R 5 is H or CH 3 ; R 6 is C 1-6 alkyl or C 3-6 cycloalkyl; and A, B, D and E are each, independently, CH, N, 0 or S, wherein at least one of A, B, D and E is N, and another of A, B, D and E is N, 0 or S.",BROAD INST INC;;MASSACHUSETTS INST TECHNOLOGY,DOCKENDORFF CHRIS;;GERMAIN ANDREW;;NAG PARTHA PRATIM;;YOUNGSAYE WILLMEN;;DANDAPANI SIVARAMAN;;MUNOZ BENITO;;FALLOON PATRICK;;NIELAND THOMAS;;KRIEGER MONTY;;YU MIAO,,https://lens.org/009-156-000-854-443,Patent Application,yes,2,0,4,4,0,A61P31/14;;C07D405/14;;C07D405/14;;C07D257/04;;C07D257/04;;C07D261/08;;C07D261/08;;C07D263/32;;C07D263/32;;C07D277/30;;C07D277/30;;C07D405/04;;C07D405/04,C07D405/04;;A61K31/41;;A61P31/14;;C07D257/04;;C07D261/08;;C07D263/32;;C07D277/30,,7,5,091-498-738-349-156;;006-471-222-650-666;;091-498-738-349-156;;108-630-904-678-379;;026-159-296-350-446,20932595;;10.1016/j.jhep.2010.06.024;;10.1016/s0968-0896(02)00120-7;;12057634;;20932595;;10.1016/j.jhep.2010.06.024;;10.1021/cr0505728;;16402771;;10.1038/nprot.2007.71;;17406624,"ANDREW J. SYDER ET AL: ""Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors"", JOURNAL OF HEPATOLOGY, vol. 54, no. 1, 2011, pages 48 - 55, XP027542100, ISSN: 0168-8278, [retrieved on 20100821];;KAZUYA YOSHIIZUMI ET AL: ""Studies on scavenger receptor inhibitors. Part 1: synthesis and structure-activity relationships of novel derivatives of sulfatides"", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 10, no. 8, 2002, pages 2445 - 2460, XP008092387, ISSN: 0968-0896, DOI: 10.1016/S0968-0896(02)00120-7;;SYDER ET AL., J. HEPATOLOGY, vol. 54, no. 1, January 2011 (2011-01-01), pages 48 - 55;;REMINGTON'S: ""The Science and Practice of Pharmacy"", 1995, MACK PUB. CO.;;UGI, I.; MEYR, R.; FETZER, U.; STEINBRUCKNER, C.: ""Versuche mit Isonitrilen"", ANGEW. CHEM., vol. 71, 1959, pages 386;;DOMLING, A.: ""Recent developments in isocyanide based multicomponent reactions in applied chemistry"", CHEM. REV., vol. 106, 2006, pages 17 - 89;;MARCACCINI, S.; TORROBA, T.: ""The use of the Ugi four-component condensation"", NATURE PROTOCOLS, vol. 2, 2007, pages 632 - 639",PENDING
14,WO,A8,WO 2014/063168 A8,055-766-801-624-089,2015-05-07,2015,US 2013/0065991 W,2013-10-21,US 201261716118 P,2012-10-19,HETEROCYCLE-BISAMIDE INHIBITORS OF SCAVENGER RECEPTOR BI,"This appl ication describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, wh ich compounds and methods can be used, for example, to med iate h igh-density l ipoprotein (H DL) l ipid uptake and treat hepatitis C vira l infections. The compounds have the formu la : wherein R 1 and R 2 are independently H, halogen, cyano, haloalkyl, ha loa lkyloxy or OMe; or R 1 and R 2 together are -O-CH 2 -O- or -0- CF 2 -O-; R 3 is H, ha logen, cyano, ha loalkyl or ha loa lkyloxy; R 4 is C 1-6 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkylmethyl or C 3-6 cycloheteroalkyl, wherein the heteroatom is N or 0; R 5 is H or CH 3 ; R 6 is C 1-6 alkyl or C 3-6 cycloalkyl; and A, B, D and E are each, independently, CH, N, 0 or S, wherein at least one of A, B, D and E is N, and another of A, B, D and E is N, 0 or S.",BROAD INST INC;;MASSACHUSETTS INST TECHNOLOGY,DOCKENDORFF CHRIS;;GERMAIN ANDREW;;NAG PARTHA PRATIM;;YOUNGSAYE WILLMEN;;DANDAPANI SIVARAMAN;;MUNOZ BENITO;;FALLOON PATRICK;;NIELAND THOMAS;;KRIEGER MONTY;;YU MIAO,,https://lens.org/055-766-801-624-089,Amended Application,yes,0,0,4,4,0,A61P31/14;;C07D405/14;;C07D405/14;;C07D257/04;;C07D257/04;;C07D261/08;;C07D261/08;;C07D263/32;;C07D263/32;;C07D277/30;;C07D277/30;;C07D405/04;;C07D405/04,C07D405/04;;A61K31/41;;A61P31/14;;C07D257/04;;C07D261/08;;C07D263/32;;C07D277/30,,0,0,,,,PENDING
15,US,A1,US 2015/0284371 A1,171-194-023-858-560,2015-10-08,2015,US 201314436610 A,2013-10-21,US 201314436610 A;;US 201261716118 P;;US 2013/0065991 W,2012-10-19,HETEROCYCLE-BISAMIDE INHIBITORS OF SCAVENGER RECEPTOR BI,"This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can be used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections. The compounds have the formula: wherein R 1 and R 2 are independently H, halogen, cyano, haloalkyl, haloalkyloxy or OMe; or R 1 and R 2 together are —O—CH 2 — or -0- CF 2 —O—; R 3 is H, halogen, cyano, haloalkyl or haloalkyloxy; R 4 is C 1-6 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkylmethyl or C 3-6 cycloheteroalkyl, wherein the heteroatom is N or 0; R 5 is H or CH 3 ; R 6 is C 1-6 alkyl or C 3-6 cycloalkyl; and A, B, D and E are each, independently, CH, N, 0 or S, wherein at least one of A, B, D and E is N, and another of A, B, D and E is N, 0 or S.",BROAD INST INC;;MASSACHUSETTS INST TECHNOLOGY,DOCKENDORFF CHRIS;;GERMAIN ANDREW;;NAG PARTHA PRATIM;;YOUNGSAYE WILLMEN;;DANDAPANI SIVARAMAN;;MUNOZ BENITO;;FALLOON PATRICK;;NIELAND THOMAS;;KRIEGER MONTY;;YU MIAO,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2015-09-02);;THE BROAD INSTITUTE INC (2016-05-03),https://lens.org/171-194-023-858-560,Patent Application,yes,0,1,4,4,0,A61P31/14;;C07D405/14;;C07D405/14;;C07D257/04;;C07D257/04;;C07D261/08;;C07D261/08;;C07D263/32;;C07D263/32;;C07D277/30;;C07D277/30;;C07D405/04;;C07D405/04,C07D405/14;;C07D257/04;;C07D261/08;;C07D263/32;;C07D277/30;;C07D405/04,,0,0,,,,ACTIVE
16,US,A1,US 2016/0060254 A1,037-368-163-314-636,2016-03-03,2016,US 201314436626 A,2013-10-21,US 201314436626 A;;US 201261716136 P;;US 2013/0065988 W,2012-10-19,THIAZOLE-BASED INHIBITORS OF SCAVENGER RECEPTOR BI,"This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections.",DOCKENDORFF CHRIS;;YOUNGSAYE WILLMEN;;NAG PARTHA PRATIM;;LEWIS TIMOTHY A;;DANDAPANI SIVARAMAN;;MUNOZ BENITO;;FALLOON PATRICK;;NIELAND THOMAS;;KRIEGER MONTY;;YU MIAO,DOCKENDORFF CHRIS;;YOUNGSAYE WILLMEN;;NAG PARTHA PRATIM;;LEWIS TIMOTHY A;;DANDAPANI SIVARAMAN;;MUNOZ BENITO;;FALLOON PATRICK;;NIELAND THOMAS;;KRIEGER MONTY;;YU MIAO,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2015-09-03);;THE BROAD INSTITUTE INC (2016-05-03),https://lens.org/037-368-163-314-636,Patent Application,yes,1,0,3,3,0,A61P31/12;;C07D417/04;;C07D417/04;;C07D277/44;;C07D277/44;;C07D417/12;;C07D417/12;;C07D417/14;;C07D417/14;;C07D491/048;;C07D491/048,C07D417/04;;C07D417/14;;C07D491/048,,29,0,,,"Chemical Abstracts Registry Number 847731-88-8, indexed in the Registry file on STN CAS ONLINE March 31, 2005.;;Chemical Abstracts Registry Number 794575-89-6, indexed in the Registry file on STN CAS ONLINE December 8, 2004.;;Chemical Abstracts Registry Number 837419-84-8, indexed in the Registry file on STN CAS ONLINE February 25, 2005.;;Chemical Abstracts Registry Number 838087-09-5, indexed in the Registry file on STN CAS ONLINE February 27, 2005.;;PubChem CID 1458848 - National Center for Biotechnology Information. PubChem Compound Database; CID=1458848, https://pubchem.ncbi.nlm.nih.gov/compound/1458848 (accessed May 4, 2016), create date July 11, 2005.;;PubChem CID 28861334 - National Center for Biotechnology Information. PubChem Compound Database; CID=28861334, https://pubchem.ncbi.nlm.nih.gov/compound/28861334 (accessed May 4, 2016), create date May 28, 2009.;;PubChem CID 36288428 - National Center for Biotechnology Information. PubChem Compound Database; CID=36288428, https://pubchem.ncbi.nlm.nih.gov/compound/36288428 (accessed May 4, 2016), create date May 29, 2009.;;PubChem CID 53347984 - National Center for Biotechnology Information. PubChem Compound Database; CID=53347984, https://pubchem.ncbi.nlm.nih.gov/compound/53347984 (accessed October 7, 2016), create date September 2, 2011.;;PubChem CID 53347941 - National Center for Biotechnology Information. PubChem Compound Database; CID=53347941, https://pubchem.ncbi.nlm.nih.gov/compound/53347941 (accessed October 7, 2016), create date September 2, 2011.;;PubChem CID 53377439 - National Center for Biotechnology Information. PubChem Compound Database; CID=53377439, https://pubchem.ncbi.nlm.nih.gov/compound/53377439 (accessed Oct. 7, 2016), create date October 4, 2011.;;PubChem CID 1451020 - National Center for Biotechnology Information. PubChem Compound Database; CID=1451020, https://pubchem.ncbi.nlm.nih.gov/compound/1451020 (accessed October 7, 2016), create date July 11, 2005;;PubChem CID 1458353 - National Center for Biotechnology Information. PubChem Compound Database; CID=1458353, https://pubchem.ncbi.nlm.nih.gov/compound/1458353 (accessed October 7, 2016), create date July 11, 2005.;;PubChem CID 1458888 - National Center for Biotechnology Information. PubChem Compound Database; CID=1458888, https://pubchem.ncbi.nlm.nih.gov/compound/1458888 (accessed October 7, 2016), create date July 11, 2005.;;PubChem CID 43816469 - National Center for Biotechnology Information. PubChem Compound Database; CID=43816469, https://pubchem.ncbi.nlm.nih.gov/compound/43816469 (accessed October 7, 2016), create date July 21, 2009.;;PubChem CID 53347940 - National Center for Biotechnology Information. PubChem Compound Database; CID=53347940, https://pubchem.ncbi.nlm.nih.gov/compound/53347940 (accessed Oct.ober 7, 2016), create date September 2, 2011.;;PubChem CID 53347958 - National Center for Biotechnology Information. PubChem Compound Database; CID=53347958, https://pubchem.ncbi.nlm.nih.gov/compound/53347958 (accessed October 7, 2016), create date September 2, 2011.;;Chemical Abstracts Registry Number 837418-96-9, indexed in the Registry file on STN CAS ONLINE February 25, 2005.;;Chemical Abstracts Registry Number 837418-97-0, indexed in the Registry file on STN CAS ONLINE February 25, 2005.;;PubChem CID 1458965 - National Center for Biotechnology Information. PubChem Compound Database; CID=1458965, https://pubchem.ncbi.nlm.nih.gov/compound/1458965 (accessed March 2, 2017), create date July 11, 2005.;;PubChem CID 1459074 - National Center for Biotechnology Information. PubChem Compound Database; CID=1459074, https://pubchem.ncbi.nlm.nih.gov/compound/1459074 (accessed March 2, 2017), create date July 11, 2005.;;PubChem CID 1459077 - National Center for Biotechnology Information. PubChem Compound Database; CID=1459077, https://pubchem.ncbi.nlm.nih.gov/compound/1459077 (accessed March 2, 2017), create date July 11, 2005.;;PubChem CID 1458885 - National Center for Biotechnology Information. PubChem Compound Database; CID=1458885, https://pubchem.ncbi.nlm.nih.gov/compound/1458885 (accessed March 2, 2017), create date July 11, 2005.;;PubChem CID 1458868 - National Center for Biotechnology Information. PubChem Compound Database; CID=1458868, https://pubchem.ncbi.nlm.nih.gov/compound/1458868 (accessed March 2, 2017), create date July 11, 2005.;;Chemical Abstracts Registry Number 846573-92-0, indexed in the Registry file on STN CAS ONLINE March 22, 2005.;;Chemical Abstracts Registry Number 838090-02-1, indexed in the Registry file on STN CAS ONLINE February 27, 2005.;;Chemical Abstracts Registry Number 838089-78-4, indexed in the Registry file on STN CAS ONLINE February 27, 2005.;;Chemical Abstracts Registry Number 838089-12-6, indexed in the Registry file on STN CAS ONLINE February 27, 2005.;;Wiley, http://www.wiley.com/legacy/Australia/Landing_Pages/Chem_1_VCE_U1&2_c08_web.pdf, Chapter 8 âOrganic Chemistryâ, pages 153-157, accessed March 3, 2017.âââââ;;Chemical Abstracts Registry Number 838089-60-4, indexed in the Registry file on STN CAS ONLINE February 27, 2005.",ACTIVE
17,WO,A1,WO 2014/063167 A1,001-157-270-828-097,2014-04-24,2014,US 2013/0065988 W,2013-10-21,US 201261716136 P,2012-10-19,THIAZOLE-BASED INHIBITORS OF SCAVENGER RECEPTOR BI,"This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections.",BROAD INST INC;;MASSACHUSETTS INST TECHNOLOGY,DOCKENDORFF CHRIS;;YOUNGSAYE WILLMEN;;NAG PARTHA PRATIM;;LEWIS TIMOTHY A;;DANDAPANI SIVARAMAN;;MUNOZ BENITO;;FALLOON PATRICK;;NIELAND THOMAS;;KRIEGER MONTY;;YU MIAO,,https://lens.org/001-157-270-828-097,Patent Application,yes,3,7,3,3,0,A61P31/12;;C07D417/04;;C07D417/04;;C07D277/44;;C07D277/44;;C07D417/12;;C07D417/12;;C07D417/14;;C07D417/14;;C07D491/048;;C07D491/048,C07D417/04;;A61K31/427;;A61P31/12;;C07D417/14,,2,1,091-498-738-349-156,20932595;;10.1016/j.jhep.2010.06.024,"SYDER, J. HCPATOLOGY V., vol. 54, no. 1, January 2011 (2011-01-01), pages 48 - 55;;""Remington's, The Science and Practice of Pharmacy"", 1995, MACK PUB. CO.",PENDING
18,CA,A1,CA 3192235 A1,023-344-383-777-46X,2021-05-14,2021,CA 3192235 A,2020-11-06,US 201962932257 P;;US 201962940164 P;;US 202063104410 P;;US 2020/0059458 W,2019-11-07,ENDOTHELIAL LIPASE ANTIBODIES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES,"The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human endothelial lipase (EL) to a subject in need thereof, for example, a subject with cardiovascular disease.",MEDIMMUNE LLC,GRIMSBY JOSEPH SAMUEL;;JIN CHAO-YU;;FALLOON JUDITH;;HSIA JUDITH ANN;;KARATHANASIS SOTIRIOS K;;GEORGE RICHARD THOMAS;;LE LAY JOHN EDWARD;;HUMMER BRIAN TIMOTHY;;HUANG YUE;;ROSENBAUM ANTON I,,https://lens.org/023-344-383-777-46X,Patent Application,no,0,0,8,8,15,A61K9/0019;;C07K2317/24;;C07K2317/76;;A61K2039/505;;C07K16/40;;A61K2039/545;;C07K2317/33;;A61K2039/507;;C07K2317/90;;A61P9/10;;A61K9/0019;;A61K2039/507;;A61K2039/545;;C07K16/40;;C07K2317/33;;C07K2317/76,A61K39/00;;A61K9/08;;A61K39/395,,0,0,,,,PENDING
19,CN,A,CN 114650839 A,131-307-626-587-322,2022-06-21,2022,CN 202080077755 A,2020-11-06,US 201962932257 P;;US 201962940164 P;;US 202063104410 P;;US 2020/0059458 W,2019-11-07,Endothelial lipase antibodies for treatment of cardiovascular diseases,"The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human endothelial lipase (EL) to a subject in need thereof, e.g., a subject having cardiovascular disease.",MILDEI MEDICAL IMMUNE LLC,GRIMSBY JOHN STEVEN;;KIM CHANG-YONG;;FALLOON JACQUES;;SIA JAIME ARTURO;;KARATANASIS SANTOSH KUMAR;;GEORGE RICHARD THOMAS JR;;LERAY JOHN E;;HAMER BRADLEY T;;HUANG YI;;ROSENBAUM ALASTAIR I,,https://lens.org/131-307-626-587-322,Patent Application,no,0,0,8,8,0,A61K9/0019;;C07K2317/24;;C07K2317/76;;A61K2039/505;;C07K16/40;;A61K2039/545;;C07K2317/33;;A61K2039/507;;C07K2317/90;;A61P9/10;;A61K9/0019;;A61K2039/507;;A61K2039/545;;C07K16/40;;C07K2317/33;;C07K2317/76,A61K39/00;;A61K9/08;;A61K39/395,,0,0,,,,PENDING
20,WO,A1,WO 2021/092421 A1,035-238-681-199-297,2021-05-14,2021,US 2020/0059458 W,2020-11-06,US 201962932257 P;;US 201962940164 P;;US 202063104410 P,2019-11-07,ENDOTHELIAL LIPASE ANTIBODIES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES,"The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human endothelial lipase (EL) to a subject in need thereof, for example, a subject with cardiovascular disease.",MEDIMMUNE LLC,GRIMSBY JOSEPH SAMUEL;;JIN CHAO-YU;;FALLOON JUDITH;;HSIA JUDITH ANN;;KARATHANASIS SOTIRIOS K;;GEORGE RICHARD THOMAS;;LE LAY JOHN EDWARD;;HUMMER BRIAN TIMOTHY;;HUANG YUE;;ROSENBAUM ANTON I,,https://lens.org/035-238-681-199-297,Patent Application,yes,2,0,8,8,15,A61K9/0019;;C07K2317/24;;C07K2317/76;;A61K2039/505;;C07K16/40;;A61K2039/545;;C07K2317/33;;A61K2039/507;;C07K2317/90;;A61P9/10;;A61K9/0019;;A61K2039/507;;A61K2039/545;;C07K16/40;;C07K2317/33;;C07K2317/76,A61K39/00;;A61K9/08;;A61K39/395,,0,0,,,,PENDING
21,TW,A,TW 202131951 A,106-201-133-736-383,2021-09-01,2021,TW 109138910 A,2020-11-06,US 201962932257 P;;US 201962940164 P;;US 202063104410 P,2019-11-07,Endothelial lipase antibodies for the treatment of cardiovascular diseases,"The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human endothelial lipase (EL) to a subject in need thereof, for example, a subject with cardiovascular disease.",MEDIMMUNE LLC,GRIMSBY JOSEPH SAMUEL;;JIN CHAO-YU;;FALLOON JUDITH;;HSIA JUDITH ANN;;KARATHANASIS SOTIRIOS K;;GEORGE RICHARD THOMAS;;LE LAY JOHN EDWARD;;HUMMER BRIAN TIMOTHY;;HUANG YUE;;ROSENBAUM ANTON I,,https://lens.org/106-201-133-736-383,Patent of Addition,no,0,0,8,8,0,A61K9/0019;;C07K2317/24;;C07K2317/76;;A61K2039/505;;C07K16/40;;A61K2039/545;;C07K2317/33;;A61K2039/507;;C07K2317/90;;A61P9/10;;A61K9/0019;;A61K2039/507;;A61K2039/545;;C07K16/40;;C07K2317/33;;C07K2317/76,A61K39/395;;A61P9/00;;A61P9/10,,0,0,,,,PENDING
22,EP,A1,EP 4054625 A1,045-671-220-008-574,2022-09-14,2022,EP 20885100 A,2020-11-06,US 201962932257 P;;US 201962940164 P;;US 202063104410 P;;US 2020/0059458 W,2019-11-07,ENDOTHELIAL LIPASE ANTIBODIES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES,,MEDIMMUNE LLC,GRIMSBY JOSEPH SAMUEL;;JIN CHAO-YU;;FALLOON JUDITH;;HSIA JUDITH ANN;;KARATHANASIS SOTIRIOS K;;GEORGE RICHARD THOMAS JR;;LE LAY JOHN EDWARD;;HUMMER BRIAN TIMOTHY;;HUANG YUE;;ROSENBAUM ANTON I,,https://lens.org/045-671-220-008-574,Patent Application,yes,0,0,8,8,15,A61K9/0019;;C07K2317/24;;C07K2317/76;;A61K2039/505;;C07K16/40;;A61K2039/545;;C07K2317/33;;A61K2039/507;;C07K2317/90;;A61P9/10;;A61K9/0019;;A61K2039/507;;A61K2039/545;;C07K16/40;;C07K2317/33;;C07K2317/76,A61K39/00;;A61K9/08;;A61K39/395,,0,0,,,,PENDING
23,AU,A1,AU 2020/378424 A1,056-789-460-600-182,2022-06-23,2022,AU 2020/378424 A,2020-11-06,US 201962932257 P;;US 201962940164 P;;US 202063104410 P;;US 2020/0059458 W,2019-11-07,Endothelial lipase antibodies for the treatment of cardiovascular diseases,"The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human endothelial lipase (EL) to a subject in need thereof, for example, a subject with cardiovascular disease.",MEDIMMUNE LLC,GRIMSBY JOSEPH SAMUEL;;JIN CHAO-YU;;FALLOON JUDITH;;HSIA JUDITH ANN;;KARATHANASIS SOTIRIOS K;;GEORGE JR RICHARD THOMAS;;LE LAY JOHN EDWARD;;HUMMER BRIAN TIMOTHY;;HUANG YUE;;ROSENBAUM ANTON I,,https://lens.org/056-789-460-600-182,Patent Application,no,0,0,8,8,0,A61K9/0019;;C07K2317/24;;C07K2317/76;;A61K2039/505;;C07K16/40;;A61K2039/545;;C07K2317/33;;A61K2039/507;;C07K2317/90;;A61P9/10;;A61K9/0019;;A61K2039/507;;A61K2039/545;;C07K16/40;;C07K2317/33;;C07K2317/76,A61K39/00;;A61K9/08;;A61K39/395,,0,0,,,,PENDING
24,US,A1,US 2023/0045712 A1,013-905-015-809-856,2023-02-09,2023,US 202017775143 A,2020-11-06,US 202017775143 A;;US 201962932257 P;;US 201962940164 P;;US 202063104410 P;;US 2020/0059458 W,2019-11-07,ENDOTHELIAL LIPASE ANTIBODIES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES,"The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human endothelial lipase (EL) to a subject in need thereof, for example, a subject with cardiovascular disease.",MEDIMMUNE LLC,GRIMSBY JOSEPH SAMUEL;;JIN CHAO-YU;;FALLOON JUDITH;;HSIA JUDITH ANN;;KARATHANASIS SOTIRIOS K;;GEORGE JR RICHARD THOMAS;;LE LAY JOHN EDWARD;;HUMMER BRIAN TIMOTHY;;HUANG YUE;;ROSENBAUM ANTON I,MEDIMMUNE LLC (2020-10-23),https://lens.org/013-905-015-809-856,Patent Application,yes,0,0,8,8,15,A61K9/0019;;C07K2317/24;;C07K2317/76;;A61K2039/505;;C07K16/40;;A61K2039/545;;C07K2317/33;;A61K2039/507;;C07K2317/90;;A61P9/10;;A61K9/0019;;A61K2039/507;;A61K2039/545;;C07K16/40;;C07K2317/33;;C07K2317/76,C07K16/40;;A61K9/00;;A61P9/10,,0,0,,,,PENDING
